<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04217447</url>
  </required_header>
  <id_info>
    <org_study_id>29BRC19.0116</org_study_id>
    <nct_id>NCT04217447</nct_id>
  </id_info>
  <brief_title>Assessment of Quitting Versus Using Aspirin Therapy In Patients Treated With Oral Anticoagulation for Atrial Fibrillation With Stabilized Coronary Artery Disease</brief_title>
  <acronym>AQUATIC</acronym>
  <official_title>Assessment of Quitting Versus Using Aspirin Therapy In Patients Treated With Oral Anticoagulation for Atrial Fibrillation With Stabilized Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Long-term aspirin (ASA) is the standard recommended antithrombotic therapy in patients
           with stable coronary artery disease (CAD), especially following stenting (Class I, Level
           A).

        -  Long-term oral anticoagulation (OAC) is the standard antithrombotic therapy in patients
           with atrial fibrillation (AF) associated with one or more risk factor for stroke (Class
           I, Level A).

        -  During the first year following acute coronary syndrome (ACS) and/or percutaneous
           coronary intervention (PCI), several studies evaluating the combination of OAC treatment
           and antiplatelet therapy are either already published or ongoing.

        -  At distance of the index ACS and/or PCI, patients with stable CAD and concomitant AF
           remain at particular high-risk of ischemic (3 to 4 times higher as compared to patients
           with stable CAD without AF) and bleeding events. Antithrombotic management of these
           patients is subsequently highly challenging in clinical practice. The European task
           force suggests that the use of a full-dose anticoagulant monotherapy without any
           antiplatelet therapy should be the default strategy in such patients with both, AF and
           stable CAD.

        -  However, evidences are sparse and weak to support such a strategy (only observational
           studies with many biases) and no randomized trial has assessed this question. These
           patients, especially those at high-risk of recurrent ischemic events (post- ACS,
           diabetes, multivessel CAD…) may benefit from the combination of OAC and aspirin at
           long-term. Indeed the crude event rate of ischemic events is much higher than the crude
           event rate of bleeding in this specific population. Ischemic events are 2 to 3 times
           more frequent than bleeding in daily practice.

        -  The benefit/risk ratio of these two different strategies (ASA in combination with OAC
           vs. OAC alone) in patients at high-risk of recurrent coronary and vascular events
           remains unknown. Dual therapy with full-dose anticoagulation and ASA may lead to higher
           risk of major bleeding, while stopping ASA in stabilized high-risk patients after PCI
           may lead to poorer outcome regarding ischemic events.

        -  The coordinating investigators therefore designed a double blind placebo controlled
           trial in order to assess the optimal antithrombotic regimen that should be pursued
           long-life in this subset of patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Long-term aspirin (ASA) is the standard recommended antithrombotic therapy in patients
           with stable coronary artery disease (CAD), especially following stenting (Class I, Level
           A).

        -  Long-term oral anticoagulation (OAC) is the standard antithrombotic therapy in patients
           with atrial fibrillation (AF) associated with one or more risk factor for stroke (Class
           I, Level A).

        -  During the first year following acute coronary syndrome (ACS) and/or percutaneous
           coronary intervention (PCI), several studies evaluating the combination of OAC treatment
           and antiplatelet therapy are either already published or ongoing.

        -  At distance of the index ACS and/or PCI, patients with stable CAD and concomitant AF
           remain at particular high-risk of ischemic (3 to 4 times higher as compared to patients
           with stable CAD without AF) and bleeding events. Antithrombotic management of these
           patients is subsequently highly challenging in clinical practice. The European task
           force suggests that the use of a full-dose anticoagulant monotherapy without any
           antiplatelet therapy should be the default strategy in such patients with both, AF and
           stable CAD.

        -  However, evidences are sparse and weak to support such a strategy (only observational
           studies with many biases) and no randomized trial has assessed this question. These
           patients, especially those at high-risk of recurrent ischemic events (post- ACS,
           diabetes, multivessel CAD…) may benefit from the combination of OAC and aspirin at
           long-term. Indeed the crude event rate of ischemic events is much higher than the crude
           event rate of bleeding in this specific population. Ischemic events are 2 to 3 times
           more frequent than bleeding in daily practice.

        -  The benefit/risk ratio of these two different strategies (ASA in combination with OAC
           vs. OAC alone) in patients at high-risk of recurrent coronary and vascular events
           remains unknown. Dual therapy with full-dose anticoagulation and ASA may lead to higher
           risk of major bleeding, while stopping ASA in stabilized high-risk patients after PCI
           may lead to poorer outcome regarding ischemic events.

      AQUATIC is a prospective, randomized, double-blind, placebo controlled, parallel-group,
      multi-center study.

      Randomization into 2 treatment groups and stratified on study center, type of OAC (VKA vs.
      DOAC), antithrombotic treatment received at the time of inclusion (dual therapy combining
      single antiplatelet therapy + OAC vs. OAC alone).

      Experimental group : Patients intaking full-dose OAC + ASA 100mg od.

      Control group : Patients intaking full-dose OAC + Placebo of ASA 100mg od.

      Note:

        -  For Apixaban: in case of &gt; 1 of the followings: &gt; 80 years old, weight &lt; 60kg,
           creatinine level &gt; 133μmol/l; Or a creatinine clearance between 30 and 50 ml/min
           (Cockroft Formula), the dose of Apixaban will be reduced to 2.5 mg bid.

        -  For Rivaroxaban: in case of moderate creatinine clearance (Cockroft Formula) (between 30
           and 50 ml/min) or severe renal insufficiency (between 15 and 29 ml/min) the dose of
           Rivaroxaban will be reduced to 15 mg od.

        -  For Dabigatran: in case of moderate creatinine clearance (Cockroft Formula) (between 30
           and 50 ml/min) with age between 75 and 80 years: the dose of Dabigatran will be 150 mg
           bid or 110 mg bid, according to the ischemic and hemorrhagic risk of the patient. In
           case of age &gt; 80 years and/or concomitant administration of Verapamil, the dose of
           Dabigatran will be reduced to 110 mg bid.

        -  For VKA: target INR (International Normalised Ratio) between 2 and 3.

      The primary efficacy objective is to demonstrate, in high-risk stabilized patients after PCI
      requiring also anticoagulation for AF, the superiority of the dual therapy ASA 100mg od +
      full-dose of OAC for 24-48 months versus full-dose of OAC alone (+ placebo) on a composite
      endpoint associating: cardio-vascular (CV) mortality, myocardial infarction, stroke, coronary
      revascularization, systemic embolism, and acute limb ischemia.

      The primary safety objective is major bleeding (ISTH : International Society of Thrombosis
      and Haemostasis).

      The secondary efficacy objectives are evaluation of efficacy of dual therapy SA 100mg od +
      OAC full ose versus OAC alone (+placebo) for:

        -  The composite of CV mortality, MI (Myocardial Infarction ), stroke

        -  CV mortality

        -  All cause death

        -  Myocardial infarction (MI)

        -  Stent thrombosis (definite or probable)

        -  Stroke (ischemic, hemorrhagic, or stroke of uncertain cause, transient ischemic attack
           [TIA])

        -  Coronary revascularization

        -  Systemic embolism

        -  Acute limb ischemia

      Net clinical benefit:

        -  All cause mortality

        -  Major bleeding [define according to the International Society of Thrombosis and
           Haemostasis (ISTH): an acute, linically overt bleeding accompanied by one or more of the
           following findings: 2g/dl decline in Hemoglobin level r = 2 red blood cell transfusions
           over a 24-hour period, leeding of a major organ (intracranial, intramedullary,
           intraocular, pericardial, interarticular, intramuscular and / or retro peritoneal) or
           fatal bleeding]

        -  Thrombotic cardiovascular events:

             -  Myocardial infarction

             -  Stent thrombosis

             -  Stroke (ischemic, hemorrhagic, or stroke of uncertain cause, TIA)

             -  Any coronary revascularization

             -  Systemic embolism

             -  Acute limb ischemia

      The secondary safety objectives are :

        -  Major and clinically relevant non major bleeding (ISTH)

        -  Major bleeding (TIMI : Thrombolysis In Myocardial Infarction)

        -  Major bleeding (BARC ≥3 : Bleeding Academic Research Consortium)

      All the included patients will be randomized at visit 1 and followed every 6 months until
      death or the end of the study (i.e. achievement of 2-year follow-up of the last included
      patient, maximum of 48 month followup for the first included patient).The first patient may
      require up to 9 visits .

      2000 patients are expected to be included.

      Inclusion period : 24 months. Duration of patient's participation: 24 to 48 months depending
      of time of inclusion.

      Total study duration: 48 months.

      All included patients will remain in the study until death or the end of the trial (i.e.
      achievement of 2-year follow-up of the last included patient).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>It's a prospective, randomized, double-blind, placebo controlled, parallel-group, multi-center study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary efficacy outcome : rate of composite of cardiovascular mortality and thrombotic cardiovascular events</measure>
    <time_frame>within 24-48 months</time_frame>
    <description>The primary efficacy outcome is the incidence of the adjudicated composite of (within 24-48 months):
CV mortality
Thrombotic cardiovascular events
Myocardial infarction
Stroke
Any coronary revascularization
Systemic embolism
Acute limb ischemia
An Independent Clinical Events Committee (ICEC) will adjudicate all events (ischemic and bleeding events).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary safety outcome : rate of major bleeding</measure>
    <time_frame>within 24-48 months</time_frame>
    <description>The primary safety outcome is the occurrence of major bleeding according to the ISTH (International Society of Thrombosis and Haemostasis) definition</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary efficacy outcomes : rate of composite of CV mortality, MI, stroke; CV mortality; all cause of death; thrombotic cardiovascular events.</measure>
    <time_frame>within 24-48 months</time_frame>
    <description>The secondary efficacy outcomes are the occurrence of any of the following events:
The composite of CV mortality, MI, stroke
CV mortality
All cause death
Thrombotic cardiovascular events:
Myocardial infarction
Stent thrombosis alone (definite or probable)
Stroke (ischemic, hemorrhagic, or stroke of uncertain cause, TIA)
Any coronary revascularization
Systemic embolism
Acute limb ischemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary safety outcomes : rate of major and clinically relevant non major bleeding</measure>
    <time_frame>within 24-48 months</time_frame>
    <description>The secondary safety outcome are the occurrence of :
Major and clinically relevant non major bleeding according to the ISTH definition (ISTH : International Society of Thrombosis and Haemostasis) Major bleeding (TIMI : Thrombolysis in Myocardial Infarction) Major bleeding (BARC ≥3 : Bleeding Academic Research Consensus)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients intaking full-dose OAC + ASA 100mg od</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients intaking full-dose OAC + Placebo of ASA 100mg od</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OAC + Aspirin 100mg od</intervention_name>
    <description>Patients will receive full-dose of OAC + Aspirin 100mg od during 24 to 48 months (until death or the end of the study : i.e. achievement of 2-year follow-up of the last included patient, maximum of 48-month followup for the first included patient)</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OAC + placebo of Aspirin 100mg od</intervention_name>
    <description>Patients will receive full-dose of OAC + placebo of Aspirin 100mg od during 24 to 48 months (until death or the end of the study : i.e. achievement of 2-year follow-up of the last included patient, maximum of 48-month followup for the first included patient)</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt;18 year-old

          -  All patients that need anticoagulation with direct oral anticoagulant (DOAC) or
             vitamin K antagonist (VKA) for AF (paroxysmal, persistent or permanent) and have a
             stabilized CAD (free from MI, or coronary revascularization in the past year) but
             remain at high residual risk of recurrent coronary and vascular events. The use of
             DOAC will be promoted as recommended by guidelines.

          -  Two different categories of patients could be included in the study, i) patients
             treated at the time of inclusion with the association of OAC and single antiplatelet
             therapy, it will be tested for them aspirin vs. interruption of antiplatelet therapy
             ii) patients treated with OAC alone at the time of inclusion, it will be tested for
             them administration of aspirin vs. no additional treatment with aspirin.

          -  High-risk of coronary and vascular event is defined as follow :

               1. History of PCI during an ACS involving placement of ≥1 stent(s) since &gt;1 year.

               2. History of PCI (&gt;1year) outside the context of ACS but with high-risk features of
                  ischemic event recurrences defined as: diabetes, or diffuse multivessel disease
                  (defined by the involvement of the 3 coronary vessels), or chronic kidney disease
                  (creatinine clearance &lt; 50ml/min), or prior stent thrombosis, or complex PCI
                  (defined by: stenting of the last remaining patent coronary artery, left main, at
                  least 3 stents implanted and/or 3 lesions treated, bifurcation with two stents,
                  length of stent &gt;60mm and chronic total coronary occlusion) or the presence of
                  peripheral artery disease (previous limb revascularization bypass or percutaneous
                  angioplasty, previous limb or foot amputation for arterial vascular disease,
                  history of intermittent claudication of peripheral artery stenosis (≥50%)
                  ,previous carotid revascularization or carotid stenosis ≥50%).

          -  Women of childbearing potential with effective contraception defined as

               -  combined (estrogen and progestogen containing) hormonal contraception associated
                  with inhibition of ovulation :

                    -  oral

                    -  intravaginal

                    -  transdermal

               -  progestogen-only hormonal contraception associated with inhibition of ovulation :

                    -  oral

                    -  injectable

                    -  implantable

               -  intrauterine device (IUD)

               -  intrauterine hormone-releasing system ( IUS)

               -  bilateral tubal occlusion

               -  vasectomised partner

               -  sexual abstinence

        Exclusion Criteria:

          -  Any coronary event within a year prior to randomization

          -  High risk of bleeding defined as recent (≤6 months) ISTH major bleeding event

          -  Constitutional or acquired haemorrhagic disease including gastrointestinal bleeding
             and thrombocytopenia

          -  Planned PCI within the next 6 months after randomization or subject requiring P2Y12
             receptor antagonist therapy

          -  Stroke within 1 month or any history of hemorrhagic stroke

          -  Any contraindication to aspirin (ASA) or any of these excipients or other NSAIDs
             (hypersensitivity, allergy, active bleeding)

          -  Any contraindication to anticoagulant

          -  History (s) of asthma induced by the administration of salicylates or substances of
             close activity (especially NSAIDs)

          -  Evolutionary gastroduodenal ulcer

          -  Any other gastroduodenal history

          -  Severe renal insufficiency

          -  Severe hepatic insufficiency

          -  Severe, uncontrolled heart failure

          -  Lactose intolerance

          -  Pregnancy

          -  Breastfeeding patients

          -  Unable (protected adults : tutorship, curatorship) orunwilling to consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Martine GILARD, PhD</last_name>
    <phone>2 98 34 75 03</phone>
    <phone_ext>+33</phone_ext>
    <email>martine.gilard@chu-brest.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie DURANTI</last_name>
    <email>marie.duranti@chu-brest.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHRU d'Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Laurent LEBORGNE, PUPH</last_name>
      <email>leborgnelaurent@chu-amiens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Alain FURBER, PU</last_name>
      <email>alfurber@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH d'Annecy-Genevois</name>
      <address>
        <city>Annecy</city>
        <zip>74370</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Loic BELLE, PU</last_name>
      <email>loic.belle@wanadoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH d'Antibes</name>
      <address>
        <city>Antibes</city>
        <zip>06606</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anne BELLEMAIN-APPAIX, PU</last_name>
      <email>anne.bellemain-appaix@ch-antibes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital privé d'Antony</name>
      <address>
        <city>Antony</city>
        <zip>92160</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Patrick DUPOUY, PU</last_name>
      <email>pdupouy@club-internet.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH d'Arras</name>
      <address>
        <city>Arras</city>
        <zip>62000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Damien BROUCQSAULT, PU</last_name>
      <email>damien.broucqsault@gh-artoisternois.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH d'Avignon</name>
      <address>
        <city>Avignon</city>
        <zip>84902</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Michel PANSIERI, PU</last_name>
      <email>mpansieri@ch-avignon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de la Côte Basque - Bayonne</name>
      <address>
        <city>Bayonne</city>
        <zip>64100</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean Noel LABEQUE, PU</last_name>
      <email>dr.jnlabeque@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut Lévêque -CHU Bordeaux-Pessac</name>
      <address>
        <city>Bordeaux</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pierre COSTE, PUPH</last_name>
      <email>pierre.coste@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Romain DIDIER, PH</last_name>
      <email>romain.didier@chu-brest.fr</email>
    </contact>
    <contact_backup>
      <last_name>Marie DURANTI</last_name>
      <email>marie.duranti@chu-brest.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hôpital Louis Pradel - Bron</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>François DERIMAY, PU</last_name>
      <email>fderimay@hotmail.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Pierre Nouveau -Cannes</name>
      <address>
        <city>Cannes</city>
        <zip>06414</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Gilles ZEMOUR, PU</last_name>
      <email>g.zemour@ch-cannes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier René Dubos - Cergy Pontoise</name>
      <address>
        <city>Cergy-Pontoise</city>
        <zip>95301</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Véronique DECALF, PU</last_name>
      <email>veronique.decalf@ght-novo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Louis Pasteur - Chartres - Le Coudray</name>
      <address>
        <city>Chartres</city>
        <zip>28630</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Grégoire RANGE, PU</last_name>
      <email>grange@ch-chartres.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pascal MOTREFF, PUPH</last_name>
      <email>pmotreff@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Sud Francilien Corbeil-Essonnes</name>
      <address>
        <city>Corbeil-Essonnes</city>
        <zip>91106</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pascal GOUBE</last_name>
      <email>pascal.goube@ch-sud-francilien.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor - Créteil</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Romain GALLET, PU</last_name>
      <email>romain.gallet@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Yves COTTIN, PUPH</last_name>
      <email>yves.cottin@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GHM - Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38028</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Damien GUIJARRO, PU</last_name>
      <email>d.guijarro@ghm-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Gerald VANZETTO, PUPH</last_name>
      <email>GVanzetto@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique St Clothilde -La Réunion</name>
      <address>
        <city>La Réunion</city>
        <zip>97400</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lucas MORLON, PU</last_name>
      <email>lucasmorlon@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Lens</name>
      <address>
        <city>Lens</city>
        <zip>62300</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Hugo VERHEYDE, PU</last_name>
      <email>mebouviez@ch-lens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Gilles LEMESLE, PUPH</last_name>
      <email>Gilles.LEMESLE@CHRU-LILLE.FR</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Victor ABOYANS, PUPH</last_name>
      <email>victor.aboyans@chu-limoges.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH St Joseph-St Luc Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69007</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Olivier DUBREUIL, PU</last_name>
      <email>odubreuil@chsjsl.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marseille-Hôpital Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13015</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Laurent BONELLO, PUPH</last_name>
      <email>laurent.bonello@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marseille- Hôpital La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Thomas CUISSET, PUPH</last_name>
      <email>thomas.cuisset@mail.ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Les Fontaines - Melun</name>
      <address>
        <city>Melun</city>
        <zip>77000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Eduardo APTECAR, PU</last_name>
      <email>eaptecar@club-internet.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHR de Metz</name>
      <address>
        <city>Metz</city>
        <zip>57085</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Khalifé KHALIFE, PU</last_name>
      <email>k.khalife@chr-metz-thionville.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GHI Le Raincy-Montfermeil</name>
      <address>
        <city>Montfermeil</city>
        <zip>93370</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Olivier NALLET, PU</last_name>
      <email>onallet@ch-montfermeil.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>24298</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Florence LECLERCQ, PUPH</last_name>
      <email>f-leclercq@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique du Millénaire - Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Christophe PIOT, PUPH</last_name>
      <email>scpcardio@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nîmes</name>
      <address>
        <city>Nîmes</city>
        <zip>30000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Guillaume CAYLA, PUPH</last_name>
      <email>guillaume.cayla@chu-nimes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHR d'Orléans</name>
      <address>
        <city>Orléans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marc GORALSKI, PU</last_name>
      <email>marc.goralski@chr-orleans.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paris-Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean-Guillaume DILLINGER, PU</last_name>
      <email>jean-guillaume.dillinger@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paris-St Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Franck BOCCARA, PUPH</last_name>
      <email>franck.boccara@sat.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paris-Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Mathieu KERNEIS, PU</last_name>
      <email>mathieu.kerneis@bidmc.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paris-HEGP Cardiologie</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Etienne PUYMIRAT, PU</last_name>
      <email>etienne.puymirat@egp.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paris-HEGP Médecine vasculaire</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Emmanuel MESSAS, PUPH</last_name>
      <email>emmanuel.messas@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paris-Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Grégory DUCROCQ, PUPH</last_name>
      <email>gregory.ducrocq@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Pau</name>
      <address>
        <city>Pau</city>
        <zip>64000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Nicolas DELARCHE, PU</last_name>
      <email>N.Delarche@wanadoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Hervé LEBRETON, PUPH</last_name>
      <email>herve.le.breton@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique St Hilaire - Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Matthieu GODIN, PU</last_name>
      <email>mgodin@clinique-sainthilaire.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Eric DURAND, PUPH</last_name>
      <email>eric.durand@chu-rouen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Seclin</name>
      <address>
        <city>Seclin</city>
        <zip>59113</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Alessandro COSENZA, PU</last_name>
      <email>alessandro.cosenza@ghsc.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Rhena - Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Nicolas LHOEST, PU</last_name>
      <email>scpcardio@noos.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Patrick OHLMANN, PUPH</last_name>
      <email>patrick.ohlmann@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Thibault LHERMUSIER, PU</last_name>
      <email>lhermusier.t@chu-toulouse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur-Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Antoine SAUGUET, PU</last_name>
      <email>a.sauguet@clinique-pasteur.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37170</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Denis ANGOULVANT, PUPH</last_name>
      <email>d.angoulvant@chu-tours.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital André Mignot - CH de Versailles</name>
      <address>
        <city>Versailles</city>
        <zip>78153</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean Louis GEORGES, PU</last_name>
      <email>j.georges@ch-versailles.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 31, 2019</study_first_submitted>
  <study_first_submitted_qc>December 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2020</study_first_posted>
  <last_update_submitted>January 3, 2020</last_update_submitted>
  <last_update_submitted_qc>January 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>oral anticoagulation</keyword>
  <keyword>antithrombotic therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

